Skip to content

US · ALNY · BIOTECHNOLOGY

Alnylam Pharmaceuticals, Inc. (ALNY) intrinsic value and stock valuation

$143.82as of 2026-11-21 · Mkt cap 30.6B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alnylam Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ALNY with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ALNY’s statements →

Alnylam Pharmaceuticals, Inc. Graham Number

Graham Number: $18.02d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 alnylam.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$3.71B+49.8% 5y CAGRd
20112025
Net income
$313.8M
20112025
Free cash flow
$465.4M
20112025
Total equity
$789.2M-4.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$3.71B$2.25B$1.83B$1.04B$844.3M
Operating income$501.6M-$-176.88M-$-282.18M-$-785.07M-$-708.65M
Net income$313.8M-$-278.16M-$-440.24M-$-1.13B-$-852.82M
EPSd$2.33M-$-2.18M-$-3.52M-$-9.3M-$-7.2M
Operating cash flow$524.1M-$-8.31M$104.2M-$-541.27M-$-641.69M
Capital expenditure-$-58.7M-$-34.28M-$-62.21M-$-72.06M-$-76.37M
Free cash flow$465.4M-$-42.59M$42M-$-613.33M-$-718.07M
Total assets$4.97B$4.24B$3.83B$3.55B$3.64B
Total debt$1.28B$1.3B$1.31B$1.32B$997.6M
Net debt-$-378.86M$329.6M$492.7M$453.9M$177.6M
Total equity$789.2M$67.1M-$-220.64M-$-158.22M$588.2M
Cash and short-term investments$2.91B$2.69B$2.44B$2.19B$2.44B
Income statement
20252024202320222021
Revenue$3.71B$2.25B$1.83B$1.04B$844.3M
Cost of revenue$677.2M$323.4M$310.4M$168.8M$140.1M
Gross profit$3.04B$1.92B$1.52B$868.6M$704.1M
Research and development expenses$1.32B$1.13B$1B$883M$792.2M
Selling, general and administrative expenses$1.21B$975.5M$795.7M$770.7M$620.6M
Other expenses$0.00$0.00$0.00$0.00-$-2.05M
Operating expenses$2.54B$2.1B$1.8B$1.65B$1.41B
Cost and expenses$3.21B$2.43B$2.11B$1.82B$1.55B
Interest income$111.5M$122M$95.6M$24.8M$1.58M
Interest expense$252.6M$141.9M$121.2M$156M$143M
Depreciation and amortization$55.7M$56.7M$54.1M$44.5M$47.6M
Ebitda$631.4M-$-178.85M-$-258.24M-$-926.56M-$-661.56M
Operating income$501.6M-$-176.88M-$-282.18M-$-785.07M-$-708.65M
Total other income/expenses, net-$-178.43M-$-200.49M-$-151.34M-$-341.92M-$-143.49M
Income before tax$323.2M-$-377.38M-$-433.52M-$-1.13B-$-852.14M
Income tax expense$9.4M-$-99.22M$6.72M$4.16M$680K
Net income$313.8M-$-278.16M-$-440.24M-$-1.13B-$-852.82M
Weighted average shares outstanding$131M$127.7M$124.9M$121.7M$118.5M
Weighted average diluted shares outstanding$134.7M$127.7M$124.9M$121.7M$118.5M
Balance sheet
20252024202320222021
Cash and short-term investments$2.91B$2.69B$2.44B$2.19B$2.44B
Net receivables$777.6M$405.3M$327.8M$238M$198.6M
Inventory$82.7M$78.5M$89.2M$129M$86.4M
Total current assets$4.05B$3.3B$2.98B$2.69B$2.81B
Property, plant and equipment, net$708.1M$693.9M$725.8M$738.6M$733.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$915.7M$944.7M$847.2M$854.1M$834.7M
Total assets$4.97B$4.24B$3.83B$3.55B$3.64B
Accounts payable$115.7M$88.4M$55.5M$98.1M$73.4M
Short-term debt$45.5M$41.9M$41.5M$42M$40.6M
Deferred revenue$4.84M$55.5M$102.8M$42.1M$149.5M
Total current liabilities$1.47B$1.19B$967.8M$767.9M$695.7M
Long-term debt$1.23B$1.25B$1.26B$1.28B$957M
Deferred revenue, non-current$0.00$0.00$188.2M$193.8M$152.4M
Total non-current liabilities$2.71B$2.99B$3.08B$2.94B$2.36B
Capital lease obligations$270.6M$271.4M$284.6M$303.3M$321.9M
Total liabilities$4.18B$4.17B$4.05B$3.7B$3.06B
Common stock$1.32M$1.29M$1.26M$1.24M$1.2M
Retained earnings-$-6.7B-$-7.29B-$-7.01B-$-6.57B-$-5.44B
Accumulated other comprehensive income (loss)-$-20.1M-$-34.52M-$-23.38M-$-44.65M-$-33.26M
Total equity$789.2M$67.1M-$-220.64M-$-158.22M$588.2M
Total investments$1.25B$1.73B$1.63B$1.33B$1.62B
Total debt$1.28B$1.3B$1.31B$1.32B$997.6M
Net debt-$-378.86M$329.6M$492.7M$453.9M$177.6M
Cash flow statement
20252024202320222021
Net income$313.8M-$-278.16M-$-440.24M-$-1.13B-$-852.82M
Depreciation and amortization$55.7M$56.7M$97M$85.6M$89.7M
Stock-based compensation$348.2M$272.1M$221.7M$230.7M$165.7M
Change in working capital-$-444.78M-$-214.08M$10.8M-$-35.55M-$-162.82M
Accounts receivable-$-359.96M-$-86.55M-$-87.94M-$-45.6M-$-101.8M
Inventory$8.47M$13.6M$18.4M-$-34.14M-$-26.41M
Accounts payable$75.1M$91.1M$80.8M$191.8M$88.2M
Net cash provided by operating activities$524.1M-$-8.31M$104.2M-$-541.27M-$-641.69M
Investments in property, plant and equipment-$-58.7M-$-34.28M-$-62.21M-$-72.06M-$-76.37M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$436.3M-$-116.84M-$-336.35M$169.4M-$-273.3M
Common stock issued$250M$303M$147.5M$259.4M$246.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-305.19M$294.2M$172.1M$425.8M$1.25B
Net change in cash$690.2M$153.8M-$-53.67M$46.4M$323.1M
Cash at end of period$1.66B$968.7M$814.9M$868.6M$822.2M
Operating cash flow$524.1M-$-8.31M$104.2M-$-541.27M-$-641.69M
Capital expenditure-$-58.7M-$-34.28M-$-62.21M-$-72.06M-$-76.37M
Free cash flow$465.4M-$-42.59M$42M-$-613.33M-$-718.07M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alnylam Pharmaceuticals, Inc.

        Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

        CEO
        Yvonne L. Greenstreet
        Employees
        2.5K
        Beta
        0.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Alnylam Pharmaceuticals, Inc. (ALNY)?

        Alnylam Pharmaceuticals, Inc. (ALNY) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ALNY undervalued?

        ALNY trades at a price of $143.82 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.